Research programme: macrolide antibacterials - Taisho
Alternative Names: FMA 0122; FMA 0713; FMA 122; FMA 1485; TEA 0929Latest Information Update: 30 Aug 2007
At a glance
- Originator Taisho Pharmaceutical
- Class
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory tract infections
Most Recent Events
- 30 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the Bacterial Infections antimicrobial activity and pharmacodynamics sections ,
- 18 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial Infections antimicrobial activity section
- 29 Sep 2003 Data presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the Bacterial Infections pharmacodynamics section